Physician profile
Christopher Tomaino
NPI 1558594960
$6,812.08
in general payments reported to CMS, 2019-2025
32 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $238 · 2021: $1,142 · 2022: $1,387 · 2023: $1,231 · 2024: $863 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.30 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,357.62 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $426.67 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $398.61 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $279.60 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $266.10 | 2021-2025 | Entyvio, Gattex |
| Redhill Biopharma INC. | $241.36 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $218.61 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $213.74 | 2023-2025 | Ibsrela |
| Pfizer INC. | $208.28 | 2019-2025 | |
| Braintree Laboratories, INC. | $207.56 | 2019-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $187.35 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $144.21 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $138.43 | 2020-2024 | Linzess |
| Novo Nordisk INC | $129.86 | 2023-2025 | Wegovy, Saxenda |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $112.78 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $101.94 | 2019-2023 | Injectafer |
| Madrigal Pharmaceuticals | $89.94 | 2025 | Rezdiffra |
| Allergan, INC. | $71.68 | 2019 | |
| Concordia Pharmaceuticals INC. | $67.36 | 2019 | |
| Genzyme Corporation | $58.50 | 2023-2024 | |
| Ethicon US, LLC | $58.04 | 2022 | |
| Evoke Pharma, INC. | $48.94 | 2021-2022 | |
| Gilead Sciences, INC. | $44.27 | 2021 | |
| Capsovision, INC. | $25.27 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $24.40 | 2022 | |
| Axonics, INC. | $23.88 | 2021 | |
| Alfasigma USA, INC. | $19.35 | 2020 | |
| Fresenius Kabi USA, LLC | $17.86 | 2024 | Idacio |
| Shionogi INC | $16.56 | 2019 | |
| Mauna Kea Technologies, INC. | $16.32 | 2025 | |
| Acadia Pharmaceuticals INC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tomaino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.